Inspire Investing LLC Makes New $633,000 Investment in Vericel Corporation $VCEL

Inspire Investing LLC bought a new stake in Vericel Corporation (NASDAQ:VCEL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 15,766 shares of the biotechnology company’s stock, valued at approximately $633,000.

Several other institutional investors and hedge funds have also made changes to their positions in the company. MCF Advisors LLC increased its stake in Vericel by 293.0% during the 2nd quarter. MCF Advisors LLC now owns 782 shares of the biotechnology company’s stock worth $35,000 after buying an additional 583 shares during the period. Ameritas Advisory Services LLC acquired a new position in Vericel in the 2nd quarter worth $36,000. Allworth Financial LP acquired a new position in Vericel in the 2nd quarter worth $60,000. Meeder Asset Management Inc. purchased a new position in Vericel in the 1st quarter valued at about $61,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Vericel in the 2nd quarter valued at about $72,000.

Vericel Price Performance

VCEL opened at $40.26 on Friday. Vericel Corporation has a 12-month low of $28.95 and a 12-month high of $49.32. The stock has a market capitalization of $2.06 billion, a PE ratio of 85.66 and a beta of 1.02. The firm’s fifty day moving average price is $40.58 and its 200 day moving average price is $38.66.

Vericel (NASDAQ:VCEL) last announced its quarterly earnings data on Thursday, July 30th. The biotechnology company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.03) by $0.07. The company had revenue of $77.46 million during the quarter, compared to analyst estimates of $72.70 million. Vericel had a net margin of 7.91% and a return on equity of 6.91%. The firm’s revenue for the quarter was up 22.5% compared to the same quarter last year. During the same period last year, the business earned ($0.01) EPS. On average, equities research analysts forecast that Vericel Corporation will post 0.54 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on VCEL. Truist Financial lowered their target price on Vericel from $58.00 to $52.00 and set a “buy” rating for the company in a research note on Wednesday, October 14th. Weiss Ratings reiterated a “hold (c)” rating on shares of Vericel in a research note on Thursday. TD Cowen increased their price target on Vericel from $55.00 to $58.00 and gave the company a “buy” rating in a report on Friday, July 31st. HC Wainwright reissued a “buy” rating and issued a $70.00 price target on shares of Vericel in a report on Tuesday, July 28th. Finally, Canaccord Genuity Group set a $60.00 price objective on Vericel in a research note on Thursday, July 30th. Four investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Vericel currently has a consensus rating of “Moderate Buy” and an average target price of $57.20.

About Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company focused on developing and marketing advanced cell therapies and regenerative medicine products. The company serves orthopedic and burn-care markets, with an emphasis on treatments that use a patient’s own cells or biologic materials to support tissue repair and healing.

Vericel’s primary orthopedic product is MACI, an autologous cultured chondrocyte implant used to repair symptomatic cartilage defects of the knee in adults.